Testing a new oral drug targeting TREM2 for Alzheimer's disease
Official title: Evaluating a novel, orally-active TREM2-targeting drug in AD
Funded at Oregon Health & Science University · NIH-11081726 · Data updated 2026-11-12
This study is testing a new pill called Sob-AM2 to see if it can help improve brain health in people with Alzheimer's by targeting a specific protein, and researchers want to find the best dose that works well without causing side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | August 15, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $497,059 |
| NIH project number | 5R01AG079949-03 |
| Project ID | NIH-11081726 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for Alzheimer's disease or those in the early stages of the condition.
✕Less likely to help
Patients with advanced Alzheimer's disease or those without any genetic predisposition to TREM2-related inflammation may not benefit from this research.
What this research studies
This research investigates a new oral medication called Sob-AM2 that targets TREM2, a protein involved in the inflammatory response in Alzheimer's disease (AD). The study aims to optimize the dosage of Sob-AM2 to enhance TREM2 expression in the brain while minimizing toxicity. Researchers will assess the drug's effectiveness in mouse models of AD, focusing on its impact on beta-amyloid accumulation and tau pathology. By understanding how Sob-AM2 works, the research hopes to provide insights into potential treatments for AD.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that slows the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in targeting TREM2 for neurodegenerative diseases, indicating potential for success in this novel application.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Gray, Nora — Oregon Health & Science University
- Study coordinator: Gray, Nora
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.